Ana Martinez

List of Publications by Year in Descending Order

302 papers	9,320 citations	52 h-index	82 g-index
341 ext. papers	10,541 ext. citations	5.3 avg, IF	6.15 L-index

#	Paper	IF	Citations
302	TDP-43 Modulation by Tau-Tubulin Kinase 1 Inhibitors: A New Avenue for Future Amyotrophic Lateral Sclerosis Therapy.. *Journal of Medicinal Chemistry*, **2022**,	8.3	2
301	Multitarget Hybrid Fasudil Derivatives as a New Approach to the Potential Treatment of Amyotrophic Lateral Sclerosis.. *Journal of Medicinal Chemistry*, **2022**,	8.3	2
300	Naphthoquinone as a New Chemical Scaffold for Leishmanicidal Inhibitors of Leishmania GSK-3. *Biomedicines*, **2022**, 10, 1136	4.8	2
299	Molecular Alterations in Sporadic and -ALS Immortalized Lymphocytes: Towards a Personalized Therapy. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	5
298	Improved Controlled Release and Brain Penetration of the Small Molecule S14 Using PLGA Nanoparticles. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	7
297	biological activity of Mill. infusion against amyloid -peptide-induced toxicity and inhibition of GSK-3, CK-1, and BACE-1 enzymes relevant to Alzheimer's disease. *Saudi Pharmaceutical Journal*, **2021**, 29, 236-243	4.4	3
296	Developing novel classes of protein kinase CK1inhibitors by fusing [1,2,4]triazole with different bicyclic heteroaromatic systems. *European Journal of Medicinal Chemistry*, **2021**, 216, 113331	6.8	3
295	Host-Directed FDA-Approved Drugs with Antiviral Activity against SARS-CoV-2 Identified by Hierarchical In Silico/In Vitro Screening Methods. *Pharmaceuticals*, **2021**, 14,	5.2	9
294	Kinase Inhibitors as Underexplored Antiviral Agents. *Journal of Medicinal Chemistry*, **2021**,	8.3	7
293	GSK3 Inhibitor-Induced Dentinogenesis Using a Hydrogel. *Journal of Dental Research*, **2021**, 220345211020652	2	2
292	From Kinase Inhibitors to Multitarget Ligands as Powerful Drug Leads for Alzheimer's Disease using Protein-Templated Synthesis. *Angewandte Chemie*, **2021**, 133, 19493-19503	3.6	
291	Therapeutic potential of novel Cell Division Cycle Kinase 7 inhibitors on TDP-43-related pathogenesis such as Frontotemporal Lobar Degeneration (FTLD) and amyotrophic lateral sclerosis (ALS). *Journal of Neurochemistry*, **2021**, 156, 379-390	6	9
290	Protein kinase inhibitors for amyotrophic lateral sclerosis therapy. *British Journal of Pharmacology*, **2021**, 178, 1316-1335	8.6	4
289	Targeting nuclear protein TDP-43 by cell division cycle kinase 7 inhibitors: A new therapeutic approach for amyotrophic lateral sclerosis. *European Journal of Medicinal Chemistry*, **2021**, 210, 112968	6.8	9
288	Mitophagy Modulation, a New Player in the Race against ALS. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	9
287	Increasing Brain Permeability of PHA-767491, a Cell Division Cycle 7 Kinase Inhibitor, with Biodegradable Polymeric Nanoparticles. *Pharmaceutics*, **2021**, 13,	6.4	7
286	Structure-Based Design of Potent Selective Nanomolar Type-II Inhibitors of Glycogen Synthase Kinase-3*Journal of Medicinal Chemistry*, **2021**, 64, 1497-1509	8.3	2

285	Identification of potential inhibitors of protein-protein interaction useful to fight against Ebola and other highly pathogenic viruses. *Antiviral Research*, **2021**, 186, 105011	10.8	7
284	From Kinase Inhibitors to Multitarget Ligands as Powerful Drug Leads for Alzheimer's Disease using Protein-Templated Synthesis. *Angewandte Chemie - International Edition*, **2021**, 60, 19344-19354	16.4	2
283	Targeting autophagy in disease: established and new strategies. *Autophagy*, **2021**, 1-23	10.2	13
282	Tideglusib, a Non-ATP Competitive Inhibitor of GSK-3β as a Drug Candidate for the Treatment of Amyotrophic Lateral Sclerosis. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	5
281	Glycogen Synthase Kinase-3 Maleimide Inhibitors As Potential PET-Tracers for Imaging Alzheimer's Disease: C-Synthesis and Proof of Concept. *Journal of Medicinal Chemistry*, **2021**,	8.3	3
280	Small molecule inhibitors of mammalian GSK-3β promote in vitro plant cell reprogramming and somatic embryogenesis in crop and forest species. *Journal of Experimental Botany*, **2021**, 72, 7808-7825	7	1
279	Identification of Niemann-Pick C1 protein as a potential novel SARS-CoV-2 intracellular target. *Antiviral Research*, **2021**, 194, 105167	10.8	6
278	Functionalized aromatic esters of the Amaryllidaceae alkaloid haemanthamine and their in vitro and in silico biological activity connected to Alzheimer's disease. *Bioorganic Chemistry*, **2020**, 100, 103928	5.1	6
277	COVID-19: Drug Targets and Potential Treatments. *Journal of Medicinal Chemistry*, **2020**, 63, 12359-12388	8.3	207
276	Motor neuron preservation and decrease of in vivo TDP-43 phosphorylation by protein CK-1δ kinase inhibitor treatment. *Scientific Reports*, **2020**, 10, 4449	4.9	22
275	Serum- and glucocorticoid-induced kinase 1, a new therapeutic target for autophagy modulation in chronic diseases. *Expert Opinion on Therapeutic Targets*, **2020**, 24, 231-243	6.4	7
274	Deciphering the enzymatic target of a new family of antischistosomal agents bearing a quinazoline scaffold using complementary computational tools. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2020**, 35, 511-523	5.6	1
273	Tuning melatonin receptor subtype selectivity in oxadiazolone-based analogues: Discovery of QR2 ligands and NRF2 activators with neurogenic properties. *European Journal of Medicinal Chemistry*, **2020**, 190, 112090	6.8	7
272	Benzothiazole-Based LRRK2 Inhibitors as Wnt Enhancers and Promoters of Oligodendrocytic Fate. *Journal of Medicinal Chemistry*, **2020**, 63, 2638-2655	8.3	4
271	Towards discovery of new leishmanicidal scaffolds able to inhibit GSK-3. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2020**, 35, 199-210	5.6	7
270	Cognitive enhancement, TAU phosphorylation reduction, and neuronal protection by the treatment of an LRRK2 inhibitor in a tauopathy mouse model. *Neurobiology of Aging*, **2020**, 96, 148-154	5.6	3
269	Novel Curcumin-Diethyl Fumarate Hybrid as a Dualistic GSK-3β Inhibitor/Nrf2 Inducer for the Treatment of Parkinson's Disease. *ACS Chemical Neuroscience*, **2020**, 11, 2728-2740	5.7	15
268	Insights into real-time chemical processes in a calcium sensor protein-directed dynamic library. *Nature Communications*, **2019**, 10, 2798	17.4	7

267	1-Aryl-3-(4-methoxybenzyl)ureas as potentially irreversible glycogen synthase kinase 3 inhibitors: Synthesis and biological evaluation. *Bioorganic and Medicinal Chemistry Letters*, **2019**, 29, 1597-1600	2.9	6
266	New flavonoid - ,-dibenzyl(-methyl)amine hybrids: Multi-target-directed agents for Alzheimer s disease endowed with neurogenic properties. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2019**, 34, 712-727	5.6	18
265	QSAR Modelling for Drug Discovery: Predicting the Activity of LRRK2 Inhibitors for Parkinson s Disease Using Cheminformatics Approaches. *Advances in Intelligent Systems and Computing*, **2019**, 63-70	0.4	3
264	Recapitulation of Pathological TDP-43 Features in Immortalized Lymphocytes from Sporadic ALS Patients. *Molecular Neurobiology*, **2019**, 56, 2424-2432	6.2	15
263	Correction of Glycogen Synthase Kinase 3 in Myotonic Dystrophy 1 Reduces the Mutant RNA and Improves Postnatal Survival of DMSXL Mice. *Molecular and Cellular Biology*, **2019**, 39,	4.8	17
262	Discovery of novel PDE4A inhibitors as potential agents against schistosomiasis. *Future Medicinal Chemistry*, **2019**, 11, 1703-1720	4.1	4
261	Potential anti-Alzheimer effects of selected Lamiaceae plants through polypharmacology on glycogen synthase kinase-3, secretase, and casein kinase 1. *Industrial Crops and Products*, **2019**, 138, 111431	5.9	10
260	CHAPTER 8:Protein Kinase Inhibitors for the Treatment of Multiple Sclerosis. *RSC Drug Discovery Series*, **2019**, 170-196	0.6	
259	GSK-3 Inhibitors: From the Brain to the Retina and Back Again. *Advances in Experimental Medicine and Biology*, **2019**, 1185, 437-441	3.6	4
258	From simple quinoxalines to potent oxazolo[5,4-f]quinoxaline inhibitors of glycogen-synthase kinase 3 (GSK3). *Organic and Biomolecular Chemistry*, **2019**, 18, 154-162	3.9	5
257	QSAR Modelling to Identify LRRK2 Inhibitors for Parkinson's Disease. *Journal of Integrative Bioinformatics*, **2019**, 16,	3.8	6
256	TDP-43: A Key Therapeutic Target beyond Amyotrophic Lateral Sclerosis. *ACS Chemical Neuroscience*, **2019**, 10, 1183-1196	5.7	17
255	Theoretical and Experimental Approaches Aimed at Drug Design Targeting Neurodegenerative Diseases. *Processes*, **2019**, 7, 940	2.9	5
254	Driving next-generation autophagy researchers towards translation (DRIVE), an international PhD training program on autophagy. *Autophagy*, **2019**, 15, 347-351	10.2	4
253	Highly potent and selective aryl-1,2,3-triazolyl benzylpiperidine inhibitors toward butyrylcholinesterase in Alzheimer's disease. *Bioorganic and Medicinal Chemistry*, **2019**, 27, 931-943	3.4	19
252	Indazolylketones as new multitarget cannabinoid drugs. *European Journal of Medicinal Chemistry*, **2019**, 166, 90-107	6.8	12
251	Computer-aided molecular design of pyrazolotriazines targeting glycogen synthase kinase 3. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2019**, 34, 87-96	5.6	8
250	Tau Tubulin Kinase 1 (TTBK1), a new player in the fight against neurodegenerative diseases. *European Journal of Medicinal Chemistry*, **2019**, 161, 39-47	6.8	14

249	A Triazolotriazine-Based Dual GSK-3β/CK-1δ Ligand as a Potential Neuroprotective Agent Presenting Two Different Mechanisms of Enzymatic Inhibition. *ChemMedChem*, **2019**, 14, 310-314	3.7	16
248	A Focused Library of Psychotropic Analogues with Neuroprotective and Neuroregenerative Potential. *ACS Chemical Neuroscience*, **2019**, 10, 279-294	5.7	14
247	TNFα disrupts blood brain barrier integrity to maintain prolonged depressive-like behavior in mice. *Brain, Behavior, and Immunity*, **2018**, 69, 556-567	16.6	87
246	Chameleon-like behavior of indolylpiperidines in complex with cholinesterases targets: Potent butyrylcholinesterase inhibitors. *European Journal of Medicinal Chemistry*, **2018**, 145, 431-444	6.8	13
245	Amyloid β-induced impairments on mitochondrial dynamics, hippocampal neurogenesis, and memory are restored by phosphodiesterase 7 inhibition. *Alzheimerjs Research and Therapy*, **2018**, 10, 24	9	43
244	Modulation of GSK-3 provides cellular and functional neuroprotection in the rd10 mouse model of retinitis pigmentosa. *Molecular Neurodegeneration*, **2018**, 13, 19	19	15
243	1-(Benzo[d]thiazol-2-yl)-3-phenylureas as dual inhibitors of casein kinase 1 and ABAD enzymes for treatment of neurodegenerative disorders. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2018**, 33, 665-670	5.6	18
242	Tau-Centric Multitarget Approach for Alzheimer's Disease: Development of First-in-Class Dual Glycogen Synthase Kinase 3β and Tau-Aggregation Inhibitors. *Journal of Medicinal Chemistry*, **2018**, 61, 7640-7656	8.3	53
241	Deciphering the Inhibition of the Neuronal Calcium Sensor 1 and the Guanine Exchange Factor Ric8a with a Small Phenothiazine Molecule for the Rational Generation of Therapeutic Synapse Function Regulators. *Journal of Medicinal Chemistry*, **2018**, 61, 5910-5921	8.3	5
240	Neurogenic and neuroprotective donepezil-flavonoid hybrids with sigma-1 affinity and inhibition of key enzymes in Alzheimer's disease. *European Journal of Medicinal Chemistry*, **2018**, 156, 534-553	6.8	26
239	Cyclic Nucleotide-Specific Phosphodiesterases as Potential Drug Targets for Anti-Leishmania Therapy. *Antimicrobial Agents and Chemotherapy*, **2018**, 62,	5.9	12
238	Identification of new allosteric sites and modulators of AChE through computational and experimental tools. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2018**, 33, 1034-1047	5.6	21
237	High-fructose corn syrup consumption in adolescent rats causes bipolar-like behavioural phenotype with hyperexcitability in hippocampal CA3-CA1 synapses. *British Journal of Pharmacology*, **2018**, 175, 4450-4463	8.6	6
236	The adiponectin promoter activator NP-1 induces high levels of circulating TNFα and weight loss in obese (fa/fa) Zucker rats. *Scientific Reports*, **2018**, 8, 9858	4.9	5
235	Interference of the complex between NCS-1 and Ric8a with phenothiazines regulates synaptic function and is an approach for fragile X syndrome. *Proceedings of the National Academy of Sciences of the United States of America*, **2017**, 114, E999-E1008	11.5	26
234	Small molecules targeting glycogen synthase kinase 3 as potential drug candidates for the treatment of retinitis pigmentosa. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2017**, 32, 522-526	5.6	13
233	Enzymatic and solid-phase synthesis of new donepezil-based L- and d-glutamic acid derivatives and their pharmacological evaluation in models related to Alzheimer's disease and cerebral ischemia. *European Journal of Medicinal Chemistry*, **2017**, 130, 60-72	6.8	17
232	Drugs in clinical development for the treatment of amyotrophic lateral sclerosis. *Expert Opinion on Investigational Drugs*, **2017**, 26, 403-414	5.9	14

231	GSK-3β inhibitor TDZD-8 reduces neonatal hypoxic-ischemic brain injury in mice. *CNS Neuroscience and Therapeutics*, **2017**, 23, 405-415	6.8	30
230	Promoting in vivo remyelination with small molecules: a neuroreparative pharmacological treatment for Multiple Sclerosis. *Scientific Reports*, **2017**, 7, 43545	4.9	27
229	Inhibition of hippocampal long-term potentiation by high-fat diets: is it related to an effect of palmitic acid involving glycogen synthase kinase-3?. *NeuroReport*, **2017**, 28, 354-359	1.7	10
228	Pharmacological tools based on imidazole scaffold proved the utility of PDE10A inhibitors for Parkinson's disease. *Future Medicinal Chemistry*, **2017**, 9, 731-748	4.1	9
227	Subtly Modulating Glycogen Synthase Kinase 3 β: Allosteric Inhibitor Development and Their Potential for the Treatment of Chronic Diseases. *Journal of Medicinal Chemistry*, **2017**, 60, 4983-5001	8.3	36
226	A preliminary investigation of phoshodiesterase 7 inhibitor VP3.15 as therapeutic agent for the treatment of experimental autoimmune encephalomyelitis mice. *Journal of Chemical Neuroanatomy*, **2017**, 80, 27-36	3.2	14
225	The GSK-3-inhibitor VP2.51 produces antidepressant effects associated with adult hippocampal neurogenesis. *Neuropharmacology*, **2017**, 116, 174-187	5.5	18
224	Biological and Pharmacological Characterization of Benzothiazole-Based CK-1δ Inhibitors in Models of Parkinson's Disease. *ACS Omega*, **2017**, 2, 5215-5220	3.9	7
223	Medicinal and Biological Chemistry (MBC) Library: An Efficient Source of New Hits. *Journal of Chemical Information and Modeling*, **2017**, 57, 2143-2151	6.1	20
222	3-(Benzyloxy)-1-(5-[F]fluoropentyl)-5-nitro-1H-indazole: a PET radiotracer to measure acetylcholinesterase in brain. *Future Medicinal Chemistry*, **2017**, 9, 983-994	4.1	3
221	Leucine rich repeat kinase 2 (LRRK2) inhibitors based on indolinone scaffold: Potential pro-neurogenic agents. *European Journal of Medicinal Chemistry*, **2017**, 138, 328-342	6.8	14
220	Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015). *Expert Opinion on Therapeutic Patents*, **2017**, 27, 657-666	6.8	31
219	Phosphodiesterase7 Inhibition Activates Adult Neurogenesis in Hippocampus and Subventricular Zone In Vitro and In Vivo. *Stem Cells*, **2017**, 35, 458-472	5.8	28
218	From dual binding site acetylcholinesterase inhibitors to allosteric modulators: A new avenue for disease-modifying drugs in Alzheimer's disease. *European Journal of Medicinal Chemistry*, **2017**, 139, 773-791	6.8	35
217	Targeting PDE10A GAF Domain with Small Molecules: A Way for Allosteric Modulation with Anti-Inflammatory Effects. *Molecules*, **2017**, 22,	4.8	5
216	Intranasal siRNA administration reveals IGF2 deficiency contributes to impaired cognition in Fragile X syndrome mice. *JCI Insight*, **2017**, 2, e91782	9.9	17
215	Chapter 8:Medicinal Chemistry Strategies to Discover New Leishmanicidal Drugs. *RSC Drug Discovery Series*, **2017**, 153-178	0.6	2
214	Targeting TDP-43 phosphorylation by Casein Kinase-1δ inhibitors: a novel strategy for the treatment of frontotemporal dementia. *Molecular Neurodegeneration*, **2016**, 11, 36	19	37

213	New neurogenic lipoic-based hybrids as innovative Alzheimer's drugs with 1 agonism and secretase inhibition. *Future Medicinal Chemistry*, **2016**, 8, 1191-207	4.1	22
212	Stress-induced neuroinflammation is mediated by GSK3-dependent TLR4 signaling that promotes susceptibility to depression-like behavior. *Brain, Behavior, and Immunity*, **2016**, 53, 207-222	16.6	91
211	Application of BACE1 immobilized enzyme reactor for the characterization of multifunctional alkaloids from Corydalis cava (Fumariaceae) as Alzheimer's disease targets. *Fitoterapia*, **2016**, 109, 241-7	3.2	23
210	New applications for known drugs: Human glycogen synthase kinase 3 inhibitors as modulators of Aspergillus fumigatus growth. *European Journal of Medicinal Chemistry*, **2016**, 116, 281-289	6.8	7
209	Versatility of the Curcumin Scaffold: Discovery of Potent and Balanced Dual BACE-1 and GSK-3 Inhibitors. *Journal of Medicinal Chemistry*, **2016**, 59, 531-44	8.3	73
208	Enhancing cAMP Levels as Strategy for the Treatment of Neuropsychiatric Disorders. *Current Topics in Medicinal Chemistry*, **2016**, 16, 3527-3535	3	13
207	Novel Triazole-Quinoline Derivatives as Selective Dual Binding Site Acetylcholinesterase Inhibitors. *Molecules*, **2016**, 21,	4.8	32
206	Small GSK-3 Inhibitor Shows Efficacy in a Motor Neuron Disease Murine Model Modulating Autophagy. *PLoS ONE*, **2016**, 11, e0162723	3.7	10
205	Tideglusib, a chemical inhibitor of GSK3 attenuates hypoxic-ischemic brain injury in neonatal mice. *Biochimica Et Biophysica Acta - General Subjects*, **2016**, 1860, 2076-85	4	28
204	New cinnamic - N-benzylpiperidine and cinnamic - N,N-dibenzyl(N-methyl)amine hybrids as Alzheimer-directed multitarget drugs with antioxidant, cholinergic, neuroprotective and neurogenic properties. *European Journal of Medicinal Chemistry*, **2016**, 121, 376-386	6.8	37
203	Development of Blood-Brain Barrier Permeable Nitrocatechol-Based Catechol O-Methyltransferase Inhibitors with Reduced Potential for Hepatotoxicity. *Journal of Medicinal Chemistry*, **2016**, 59, 7584-97	8.3	21
202	Morphometric and neurochemical alterations found in l-BMAA treated rats. *Environmental Toxicology and Pharmacology*, **2015**, 39, 1232-45	5.8	16
201	Phosphodiesterase 7 inhibition induces dopaminergic neurogenesis in hemiparkinsonian rats. *Stem Cells Translational Medicine*, **2015**, 4, 564-75	6.9	30
200	3,4-Dihydro-1,3,5-triazin-2(1H)-ones as the First Dual BACE-1/GSK-3 Fragment Hits against Alzheimer's Disease. *ACS Chemical Neuroscience*, **2015**, 6, 1665-82	5.7	47
199	Analysis of N-methylamino-L-alanine (L-BMAA) neurotoxicity in rat cerebellum. *NeuroToxicology*, **2015**, 48, 192-205	4.4	15
198	Biology-oriented development of novel lipophilic antioxidants with neuroprotective activity. *RSC Advances*, **2015**, 5, 15800-15811	3.7	16
197	Neurogenic Potential Assessment and Pharmacological Characterization of 6-Methoxy-1,2,3,4-tetrahydro-carboline (Pinoline) and Melatonin-Pinoline Hybrids. *ACS Chemical Neuroscience*, **2015**, 6, 800-10	5.7	20
196	Multitarget drug discovery for Alzheimer's disease: triazinones as BACE-1 and GSK-3 inhibitors. *Angewandte Chemie - International Edition*, **2015**, 54, 1578-82	16.4	87

195	PDE7 inhibitor TC3.6 ameliorates symptomatology in a model of primary progressive multiple sclerosis. *British Journal of Pharmacology*, **2015**, 172, 4277-90	8.6	19
194	Impairments in cognition and neural precursor cell proliferation in mice expressing constitutively active glycogen synthase kinase-3. *Frontiers in Behavioral Neuroscience*, **2015**, 9, 55	3.5	10
193	Silencing phosphodiesterase 7B gene by lentiviral-shRNA interference attenuates neurodegeneration and motor deficits in hemiparkinsonian mice. *Neurobiology of Aging*, **2015**, 36, 1160-73	5.6	24
192	Therapeutic approaches for the future treatment of Fragile X. *Current Opinion in Behavioral Sciences*, **2015**, 4, 6-21	4	2
191	Multitarget Drug Discovery for Alzheimer's Disease: Triazinones as BACE-1 and GSK-3β Inhibitors. *Angewandte Chemie*, **2015**, 127, 1598-1602	3.6	5
190	From Bitopic Inhibitors to Multitarget Drugs for the Future Treatment of Alzheimer's Disease. *Current Medicinal Chemistry*, **2015**, 22, 3789-806	4.3	18
189	Protein kinase CK-1 inhibitors as new potential drugs for amyotrophic lateral sclerosis. *Journal of Medicinal Chemistry*, **2014**, 57, 2755-72	8.3	70
188	Cannabinoid agonists showing BuChE inhibition as potential therapeutic agents for Alzheimer's disease. *European Journal of Medicinal Chemistry*, **2014**, 73, 56-72	6.8	33
187	Modulation of cAMP-specific PDE without emetogenic activity: new sulfide-like PDE7 inhibitors. *Journal of Medicinal Chemistry*, **2014**, 57, 8590-607	8.3	18
186	cAMP-specific phosphodiesterase inhibitors: promising drugs for inflammatory and neurological diseases. *Expert Opinion on Therapeutic Patents*, **2014**, 24, 1311-21	6.8	59
185	New melatonin-N,N-dibenzyl(N-methyl)amine hybrids: potent neurogenic agents with antioxidant, cholinergic, and neuroprotective properties as innovative drugs for Alzheimer's disease. *Journal of Medicinal Chemistry*, **2014**, 57, 3773-85	8.3	70
184	Crosstalk between phosphodiesterase 7 and glycogen synthase kinase-3: two relevant therapeutic targets for neurological disorders. *ACS Chemical Neuroscience*, **2014**, 5, 194-204	5.7	16
183	Glycogen synthase kinase-3 inhibitors reverse deficits in long-term potentiation and cognition in fragile X mice. *Biological Psychiatry*, **2014**, 75, 198-206	7.9	91
182	Dibenzo[1,4,5]thiadiazepine: a hardly-known heterocyclic system with neuroprotective properties of potential usefulness in the treatment of neurodegenerative diseases. *European Journal of Medicinal Chemistry*, **2014**, 81, 350-8	6.8	11
181	CB1 blockade potentiates down-regulation of lipogenic gene expression in perirenal adipose tissue in high carbohydrate diet-induced obesity. *PLoS ONE*, **2014**, 9, e90016	3.7	12
180	Phosphodiesterase 10 inhibitors: new disease modifying drugs for Parkinson's disease?. *Current Medicinal Chemistry*, **2014**, 21, 1171-87	4.3	19
179	Glycogen Synthase Kinase-3β Expression and Phosphorylation in Peripheral Blood Mononuclear Cells of Patients with Amyotrophic Lateral Sclerosis. *British Journal of Medicine and Medical Research*, **2014**, 4, 263-271		2
178	Inhibition of endogenous phosphodiesterase 7 promotes oligodendrocyte precursor differentiation and survival. *Cellular and Molecular Life Sciences*, **2013**, 70, 3449-62	10.3	39

177	Glycogen synthase kinase-3 inhibitors as potent therapeutic agents for the treatment of Parkinson disease. *ACS Chemical Neuroscience*, **2013**, 4, 350-60	5.7	47
176	Evidence for a new binding mode to GSK-3: allosteric regulation by the marine compound palinurin. *European Journal of Medicinal Chemistry*, **2013**, 60, 479-89	6.8	47
175	Synthesis, pharmacological assessment, and molecular modeling of acetylcholinesterase/butyrylcholinesterase inhibitors: effect against amyloid-β-induced neurotoxicity. *ACS Chemical Neuroscience*, **2013**, 4, 547-65	5.7	39
174	Synthesis, pharmacological assessment, and molecular modeling of 6-chloro-pyridonepezils: new dual AChE inhibitors as potential drugs for the treatment of Alzheimer's disease. *European Journal of Medicinal Chemistry*, **2013**, 67, 64-74	6.8	24
173	A Fluorescent Styrylquinoline with Combined Therapeutic and Diagnostic Activities against Alzheimer's and Prion Diseases. *ACS Medicinal Chemistry Letters*, **2013**, 4, 225-9	4.3	36
172	Unraveling phosphodiesterase surfaces. Identification of phosphodiesterase 7 allosteric modulation cavities. *European Journal of Medicinal Chemistry*, **2013**, 70, 781-8	6.8	4
171	Comparative assessment of PDE 4 and 7 inhibitors as therapeutic agents in experimental autoimmune encephalomyelitis. *British Journal of Pharmacology*, **2013**, 170, 602-13	8.6	38
170	β-N-methylamino-l-alanine causes neurological and pathological phenotypes mimicking Amyotrophic Lateral Sclerosis (ALS): the first step towards an experimental model for sporadic ALS. *Environmental Toxicology and Pharmacology*, **2013**, 36, 243-255	5.8	46
169	Phosphodiesterase 7 inhibitor reduced cognitive impairment and pathological hallmarks in a mouse model of Alzheimer's disease. *Neurobiology of Aging*, **2013**, 34, 2133-45	5.6	64
168	Dual inhibitor of PDE7 and GSK-3-VP1.15 acts as antipsychotic and cognitive enhancer in C57BL/6J mice. *Neuropharmacology*, **2013**, 64, 205-14	5.5	36
167	Regulation of Th1 cells and experimental autoimmune encephalomyelitis by glycogen synthase kinase-3. *Journal of Immunology*, **2013**, 190, 5000-11	5.3	58
166	Multitarget cannabinoids as novel strategy for Alzheimer disease. *Current Alzheimer Research*, **2013**, 10, 229-39	3	14
165	Lessons learnt from glycogen synthase kinase 3 inhibitors development for Alzheimer's disease. *Current Topics in Medicinal Chemistry*, **2013**, 13, 1808-19	3	28
164	CHAPTER 12:Phosphodiesterase Inhibitors as a New Therapeutic Approach for the Treatment of Parkinson's Disease. *RSC Drug Discovery Series*, **2013**, 294-307	0.6	3
163	Neuroprotective efficacy of quinazoline type phosphodiesterase 7 inhibitors in cellular cultures and experimental stroke model. *European Journal of Medicinal Chemistry*, **2012**, 47, 175-85	6.8	53
162	A small chemical library of 2-aminoimidazole derivatives as BACE-1 inhibitors: Structure-based design, synthesis, and biological evaluation. *European Journal of Medicinal Chemistry*, **2012**, 48, 206-13	6.8	22
161	5-Imino-1,2-4-thiadiazoles and quinazolines derivatives as glycogen synthase kinase 3β [GSK-3β] and phosphodiesterase 7 (PDE7) inhibitors: determination of blood-brain barrier penetration and binding to human serum albumin. *European Journal of Pharmaceutical Sciences*, **2012**, 45, 677-84	5.1	20
160	Synthesis, biological assessment, and molecular modeling of racemic 7-aryl-9,10,11,12-tetrahydro-7H-benzo[7,8]chromeno[2,3-b]quinolin-8-amines as potential drugs for the treatment of Alzheimer's disease. *European Journal of Medicinal Chemistry*, **2012**, 54, 750-63	6.8	55

159	Identification in silico and experimental validation of novel phosphodiesterase 7 inhibitors with efficacy in experimental autoimmune encephalomyelitis mice. *ACS Chemical Neuroscience*, **2012**, 3, 793-803	5.7	18
158	Effect of phosphodiesterase 7 (PDE7) inhibitors in experimental autoimmune encephalomyelitis mice. Discovery of a new chemically diverse family of compounds. *Journal of Medicinal Chemistry*, **2012**, 55, 3274-84	8.3	43
157	The new iminothiadiazole derivative VP1.14 ameliorates hippocampal damage after an excitotoxic injury. *Journal of Neurochemistry*, **2012**, 122, 1193-202	6	9
156	New tacrine-4-oxo-4H-chromene hybrids as multifunctional agents for the treatment of Alzheimer's disease, with cholinergic, antioxidant, and β-amyloid-reducing properties. *Journal of Medicinal Chemistry*, **2012**, 55, 1303-17	8.3	211
155	Benzothiazepine CGP37157 and its isosteric 2'-methyl analogue provide neuroprotection and block cell calcium entry. *ACS Chemical Neuroscience*, **2012**, 3, 519-29	5.7	24
154	Pyridonepezils, new dual AChE inhibitors as potential drugs for the treatment of Alzheimer's disease: synthesis, biological assessment, and molecular modeling. *European Journal of Medicinal Chemistry*, **2012**, 57, 296-301	6.8	43
153	5-imino-1,2,4-thiadiazoles: first small molecules as substrate competitive inhibitors of glycogen synthase kinase 3. *Journal of Medicinal Chemistry*, **2012**, 55, 1645-61	8.3	61
152	Glycogen synthase kinase 3 inhibition promotes adult hippocampal neurogenesis in vitro and in vivo. *ACS Chemical Neuroscience*, **2012**, 3, 963-71	5.7	108
151	Adiponectin promoter activator NP-1 reduces body weight and hepatic steatosis in high-fat diet-fed animals. *American Journal of Physiology - Endocrinology and Metabolism*, **2012**, 302, E817-30	6	10
150	Exploring the binding sites of glycogen synthase kinase 3. Identification and characterization of allosteric modulation cavities. *Journal of Medicinal Chemistry*, **2011**, 54, 8461-70	8.3	78
149	Glycogen synthase kinase-3. *International Journal of Alzheimerjs Disease*, **2011**, 2011, 279234	3.7	3
148	Glycogen synthase kinase 3 inhibitors in the next horizon for Alzheimer's disease treatment. *International Journal of Alzheimerjs Disease*, **2011**, 2011, 280502	3.7	60
147	Phosphodiesterase 7 inhibition preserves dopaminergic neurons in cellular and rodent models of Parkinson disease. *PLoS ONE*, **2011**, 6, e17240	3.7	69
146	The potential role of glycogen synthase kinase 3 inhibitors as amyotrophic lateral sclerosis pharmacological therapy. *Current Medicinal Chemistry*, **2011**, 18, 3028-34	4.3	24
145	Reduction of body weight, liver steatosis and expression of stearoyl-CoA desaturase 1 by the isoflavone daidzein in diet-induced obesity. *British Journal of Pharmacology*, **2011**, 164, 1899-915	8.6	76
144	Switching reversibility to irreversibility in glycogen synthase kinase 3 inhibitors: clues for specific design of new compounds. *Journal of Medicinal Chemistry*, **2011**, 54, 4042-56	8.3	60
143	N-acylaminophenothiazines: neuroprotective agents displaying multifunctional activities for a potential treatment of Alzheimer's disease. *European Journal of Medicinal Chemistry*, **2011**, 46, 2224-35	6.8	42
142	Protein kinases CK1 and CK2 as new targets for neurodegenerative diseases. *Medicinal Research Reviews*, **2011**, 31, 924-54	14.4	98

141	An application of two MIFs-based tools (Volsurf+ and Pentacle) to binary QSAR: the case of a palinurin-related data set of non-ATP competitive glycogen synthase kinase 3β (GSK-3β) inhibitors. *European Journal of Medicinal Chemistry*, **2011**, 46, 860-9	6.8	22
140	GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS. *Frontiers in Molecular Neuroscience*, **2011**, 4, 32	6.1	225
139	PDE 7 inhibitors: new potential drugs for the therapy of spinal cord injury. *PLoS ONE*, **2011**, 6, e15937	3.7	52
138	Novel tacrine-8-hydroxyquinoline hybrids as multifunctional agents for the treatment of Alzheimer's disease, with neuroprotective, cholinergic, antioxidant, and copper-complexing properties. *Journal of Medicinal Chemistry*, **2010**, 53, 4927-37	8.3	218
137	Old phenothiazine and dibenzothiadiazepine derivatives for tomorrow's neuroprotective therapies against neurodegenerative diseases. *European Journal of Medicinal Chemistry*, **2010**, 45, 6152-8	6.8	39
136	NP04634 prevents cell damage caused by calcium overload and mitochondrial disruption in bovine chromaffin cells. *European Journal of Pharmacology*, **2009**, 607, 47-53	5.3	9
135	Tacrine-melatonin hybrids as multifunctional agents for Alzheimer's disease, with cholinergic, antioxidant, and neuroprotective properties. *ChemMedChem*, **2009**, 4, 828-41	3.7	132
134	Synthesis, structural analysis, and biological evaluation of thioxoquinazoline derivatives as phosphodiesterase 7 inhibitors. *ChemMedChem*, **2009**, 4, 866-76	3.7	53
133	Anticonvulsant and neuroprotective effects of the novel calcium antagonist NP04634 on kainic acid-induced seizures in rats. *Journal of Neuroscience Research*, **2009**, 87, 3687-96	4.4	15
132	Thienylhalomethylketones: Irreversible glycogen synthase kinase 3 inhibitors as useful pharmacological tools. *Bioorganic and Medicinal Chemistry*, **2009**, 17, 6914-25	3.4	44
131	The first enantioselective synthesis of palinurin. *Chemical Communications*, **2009**, 3252-4	5.8	22
130	Neuroprotective and cholinergic properties of multifunctional glutamic acid derivatives for the treatment of Alzheimer's disease. *Journal of Medicinal Chemistry*, **2009**, 52, 7249-57	8.3	85
129	PDE7 inhibitors as new drugs for neurological and inflammatory disorders. *Expert Opinion on Therapeutic Patents*, **2008**, 18, 1127-1139	6.8	37
128	Antidepressant-like effect of the novel thiadiazolidinone NP031115 in mice. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, **2008**, 32, 1549-56	5.5	105
127	Neuroprotective effect of the new thiadiazolidinone NP00111 against oxygen-glucose deprivation in rat hippocampal slices: implication of ERK1/2 and PPARgamma receptors. *Experimental Neurology*, **2008**, 212, 93-9	5.7	21
126	Potent beta-amyloid modulators. *Neurodegenerative Diseases*, **2008**, 5, 153-6	2.3	38
125	GSK-3 inhibitors: a ray of hope for the treatment of Alzheimer's disease?. *Journal of Alzheimerjs Disease*, **2008**, 15, 181-91	4.3	105
124	Preclinical efficacy on GSK-3 inhibitors: towards a future generation of powerful drugs. *Medicinal Research Reviews*, **2008**, 28, 773-96	14.4	84

123	CODES, a novel procedure for ligand-based virtual screening: PDE7 inhibitors as an application example. *European Journal of Medicinal Chemistry*, **2008**, 43, 1349-59	6.8	29
122	Non-ATP competitive glycogen synthase kinase 3beta (GSK-3beta) inhibitors: study of structural requirements for thiadiazolidinone derivatives. *Bioorganic and Medicinal Chemistry*, **2008**, 16, 495-510	3.4	53
121	Design, synthesis, and evaluation of potential inhibitors of nitric oxide synthase. *Bioorganic and Medicinal Chemistry*, **2008**, 16, 6193-206	3.4	19
120	Polyaniline-based microelectrodes for sensing ascorbic acid in beverages. *Current Applied Physics*, **2008**, 8, 320-323	2.6	32
119	NP031112, a thiadiazolidinone compound, prevents inflammation and neurodegeneration under excitotoxic conditions: potential therapeutic role in brain disorders. *Journal of Neuroscience*, **2007**, 27, 5766-76	6.6	91
118	Glycogen synthase kinase-3 (GSK-3) inhibitory activity and structure-activity relationship (SAR) studies of the manzamine alkaloids. Potential for Alzheimer's disease. *Journal of Natural Products*, **2007**, 70, 1397-405	4.9	110
117	Electron correlated ab initio study of amino group flexibility for improvement of molecular mechanics simulations on nucleic acid conformations and interactions. *Journal of Biological Physics*, **2007**, 33, 499-514	1.6	2
116	Enantioselective LC/MS method for the determination of an antimalarial agent Fenozan B07 in dog plasma. *Chirality*, **2006**, 18, 297-305	2.1	2
115	Targeting beta-amyloid pathogenesis through acetylcholinesterase inhibitors. *Current Pharmaceutical Design*, **2006**, 12, 4377-87	3.3	167
114	Novel tacrine-melatonin hybrids as dual-acting drugs for Alzheimer disease, with improved acetylcholinesterase inhibitory and antioxidant properties. *Journal of Medicinal Chemistry*, **2006**, 49, 459-62	8.3	223
113	Novel cholinesterase inhibitors as future effective drugs for the treatment of Alzheimer's disease. *Expert Opinion on Investigational Drugs*, **2006**, 15, 1-12	5.9	70
112	Manzamine B and E and ircinal A related alkaloids from an Indonesian Acanthostrongylophora sponge and their activity against infectious, tropical parasitic, and Alzheimer's diseases. *Journal of Natural Products*, **2006**, 69, 1034-40	4.9	110
111	Dual binding site acetylcholinesterase inhibitors: potential new disease-modifying agents for AD. *Journal of Molecular Neuroscience*, **2006**, 30, 85-8	3.3	28
110	Marine compounds for the therapeutic treatment of neurological disorders. *Expert Opinion on Therapeutic Patents*, **2005**, 15, 1377-1386	6.8	21
109	Regulation of inflammatory response in neural cells in vitro by thiadiazolidinones derivatives through peroxisome proliferator-activated receptor gamma activation. *Journal of Biological Chemistry*, **2005**, 280, 21453-62	5.4	155
108	Design, synthesis, and biological evaluation of dual binding site acetylcholinesterase inhibitors: new disease-modifying agents for Alzheimer's disease. *Journal of Medicinal Chemistry*, **2005**, 48, 7223-33	8.3	179
107	Design and synthesis of N-benzylpiperidine-purine derivatives as new dual inhibitors of acetyl- and butyrylcholinesterase. *Bioorganic and Medicinal Chemistry*, **2005**, 13, 6795-802	3.4	43
106	Donepezil-tacrine hybrid related derivatives as new dual binding site inhibitors of AChE. *Bioorganic and Medicinal Chemistry*, **2005**, 13, 6588-97	3.4	129

105	Molecular mechanics description of cytosine energy and geometry using preliminary ab initio results. *Computational and Theoretical Chemistry*, **2005**, 729, 59-64		3
104	Good oral absorption prediction on non-nucleoside benzothiadiazine dioxide human cytomegalovirus inhibitors using combined chromatographic and neuronal network techniques. *Bioorganic and Medicinal Chemistry Letters*, **2005**, 15, 1919-21	2.9	6
103	SAR and 3D-QSAR studies on thiadiazolidinone derivatives: exploration of structural requirements for glycogen synthase kinase 3 inhibitors. *Journal of Medicinal Chemistry*, **2005**, 48, 7103-12	8.3	102
102	Synthesis and biological evaluation of tacrine-thiadiazolidinone hybrids as dual acetylcholinesterase inhibitors. *Archiv Der Pharmazie*, **2005**, 338, 18-23	4.3	15
101	Cyclic nucleotide phosphodiesterases and their role in immunomodulatory responses: advances in the development of specific phosphodiesterase inhibitors. *Medicinal Research Reviews*, **2005**, 25, 229-44	14.4	100
100	GSK-3 inhibitors: discoveries and developments. *Current Medicinal Chemistry*, **2004**, 11, 755-63	4.3	62
99	CODES/Neural Network Model: a Useful Tool for in Silico Prediction of Oral Absorption and Blood-Brain Barrier Permeability of Structurally Diverse Drugs. *QSAR and Combinatorial Science*, **2004**, 23, 89-98		29
98	P4-428 TDZDS: GSK3□nhibitors as therapeutic agents for Alzheimer's disease and other tauopathies. *Neurobiology of Aging*, **2004**, 25, S596	5.6	3
97	Nitric oxide in the cerebral cortex of amyloid-precursor protein (SW) Tg2576 transgenic mice. *Neuroscience*, **2004**, 128, 73-89	3.9	65
96	AMPA glutamate receptors and neuropathic pain. *Mini-Reviews in Medicinal Chemistry*, **2003**, 3, 757-63	3.2	3
95	Synthesis and muscarinic activities of O-[(benzyl- or benzoyl-pyrazolyl)propynyl]-oximes of N-methylpiperidinone, 3-tropinone, and 3-quinuclidinone. *Bioorganic and Medicinal Chemistry*, **2003**, 11, 2263-8	3.4	12
94	Benzothiadiazine dioxides (BTD) derivatives as non-nucleoside human cytomegalovirus (HCMV) inhibitors. study of structural requirements for biological activity. *Bioorganic and Medicinal Chemistry*, **2003**, 11, 2395-402	3.4	5
93	Thienyl and phenyl alpha-halomethyl ketones: new inhibitors of glycogen synthase kinase (GSK-3beta) from a library of compound searching. *Journal of Medicinal Chemistry*, **2003**, 46, 4631-3	8.3	92
92	Peripheral and dual binding site inhibitors of acetylcholinesterase as neurodegenerative disease modifying agents. *Expert Opinion on Therapeutic Patents*, **2003**, 13, 1725-1732	6.8	7
91	Benzothiadiazine dioxide human cytomegalovirus inhibitors: synthesis and antiviral evaluation of main heterocycle modified derivatives. *Antiviral Chemistry and Chemotherapy*, **2003**, 14, 107-14	3.5	9
90	Peripheral and dual binding site inhibitors of acetylcholinesterase as neurodegenerative disease-modifying agents. *Expert Opinion on Therapeutic Patents*, **2003**, 13, 1725-1732	6.8	5
89	Non-cholinergic pharmacotherapy approaches to the future treatment of Alzheimer's disease. *Mini-Reviews in Medicinal Chemistry*, **2002**, 2, 37-50	3.2	28
88	Glycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation. *Medicinal Research Reviews*, **2002**, 22, 373-84	14.4	275

87	First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease. *Journal of Medicinal Chemistry*, **2002**, 45, 1292-9	8.3	383
86	Inhibitors of glycogen synthase kinase-3: future therapy for unmet medical needs?. *Expert Opinion on Therapeutic Patents*, **2002**, 12, 1527-1536	6.8	47
85	CoMFA of benzyl derivatives of 2,1,3-benzo and benzothieno[3,2-alpha]thiadiazine 2,2-dioxides: clues for the design of phosphodiesterase 7 inhibitors. *European Journal of Medicinal Chemistry*, **2001**, 36, 333-8	6.8	44
84	Recent strategies in the development of new human cytomegalovirus inhibitors. *Medicinal Research Reviews*, **2001**, 21, 227-44	14.4	25
83	Studies on the reactivity of some N-aryl- and N-heteroaryl-N'-alkylthioureas towards electrophilic reagents. Synthesis of new N-pyridylthioureas and thiazolines mar. *Journal of Heterocyclic Chemistry*, **2001**, 38, 435-441	1.9	1
82	Anti-HIV-1 activity of benzothiadiazine dioxide. *Antiviral Chemistry and Chemotherapy*, **2001**, 12, 347-51	3.5	4
81	O-Pyrazolylpropynyl-Hydroxylamines as Versatile Intermediates in the Synthesis of Compounds of Pharmacological Interest. *Synthesis*, **2001**, 2001, 1711-1715	2.9	26
80	Peripheral and dual binding site acetylcholinesterase inhibitors: implications in treatment of Alzheimer's disease. *Mini-Reviews in Medicinal Chemistry*, **2001**, 1, 267-72	3.2	116
79	Synthesis of new N-(4-pyridyl)-1-aminopyrazoles and their muscarinic and adrenergic properties. *Archiv Der Pharmazie*, **2000**, 333, 118-22	4.3	11
78	Prediction of Drug Half-life Values of Antihistamines Based on the CODES/Neural Network Model. *QSAR and Combinatorial Science*, **2000**, 19, 448-454		12
77	Regioselective lipase-catalysed monoamidation of d-glutamic acid diesters: effect of the N-protecting group. *Tetrahedron: Asymmetry*, **2000**, 11, 2537-2545		8
76	Lipase-catalysed synthesis of new acetylcholinesterase inhibitors: N-benzylpiperidine aminoacid derivatives. *Bioorganic and Medicinal Chemistry*, **2000**, 8, 731-8	3.4	11
75	N-Benzylpiperidine derivatives of 1,2,4-thiadiazolidinone as new acetylcholinesterase inhibitors. *European Journal of Medicinal Chemistry*, **2000**, 35, 913-22	6.8	73
74	Hindered Inversion/Rotation in Diheteroaryl Alkyl Amines with a N-(1-Pyrazolyl) Group: Dynamic NMR and Molecular Modelling Studies. *Tetrahedron*, **2000**, 56, 1739-1743	2.4	11
73	Novel agents for the treatment of human cytomegalovirus infection. *Expert Opinion on Therapeutic Patents*, **2000**, 10, 165-177	6.8	7
72	Thienothiadiazine 2,2-dioxide acyclonucleosides: synthesis and antiviral activity. *Antiviral Chemistry and Chemotherapy*, **2000**, 11, 221-30	3.5	3
71	Inhibition of tau phosphorylation: a new therapeutic strategy for the treatment of Alzheimer disease and other neurodegenerative disorders. *Expert Opinion on Therapeutic Patents*, **2000**, 10, 1519-1527	6.8	34
70	Benzyl derivatives of 2,1,3-benzo- and benzothieno[3,2-a]thiadiazine 2,2-dioxides: first phosphodiesterase 7 inhibitors. *Journal of Medicinal Chemistry*, **2000**, 43, 683-9	8.3	65

69	Benzothiadiazine dioxide dibenzyl derivatives as potent human cytomegalovirus inhibitors: synthesis and comparative molecular field analysis. *Journal of Medicinal Chemistry*, **2000**, 43, 3218-25	8.3	24
68	Nonnucleoside human cytomegalovirus inhibitors: synthesis and antiviral evaluation of (chlorophenylmethyl)benzothiadiazine dioxide derivatives. *Journal of Medicinal Chemistry*, **2000**, 43, 3267-73	8.3	23
67	Synthesis of New N-(4-Pyridyl)-1-aminopyrazoles and Their Muscarinic and Adrenergic Properties **2000**, 333, 118		2
66	Selective dopamine receptors: Synthesis, complexing properties, and molecular modelling studies of new podands derived from 4-hydroxy-1H-pyrazole. *Tetrahedron*, **1999**, 55, 2763-2772	2.4	17
65	Chlorophenylmethyl benzothiadiazine dioxides derivatives: potent human cytomegalovirus inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **1999**, 9, 3133-6	2.9	9
64	Imidazothiadiazine dioxides: synthesis and antiviral activity. *Bioorganic and Medicinal Chemistry*, **1999**, 7, 1617-23	3.4	14
63	On the tautomerism of 2,1,3-benzothiadiazinone S,S-dioxide and related compounds. *Tetrahedron*, **1999**, 55, 12405-12410	2.4	11
62	Candida antarctica lipase B catalysed amidation of pyroglutamic acid derivatives. A reaction survey. *Journal of Molecular Catalysis B: Enzymatic*, **1999**, 7, 299-306		9
61	Intramolecular oxidative cyclizations in heteroarylthioureas: A versatile pathway to bridgehead heterocyclic systems. *Journal of Heterocyclic Chemistry*, **1999**, 36, 991-995	1.9	11
60	Synthesis and potential muscarinic receptor binding and antioxidant properties of 3-(thiadiazolyl)pyridine 1-oxide compounds. *Archiv Der Pharmazie*, **1999**, 332, 191-4	4.3	29
59	Regioselective Lipase-Catalysed Amidation of Dicarboxylic N-Blocked Amino Acid Diesters Effect of the Side-Chain Length. *European Journal of Organic Chemistry*, **1999**, 1999, 2835-2839	3.2	5
58	Novel potential agents for human cytomegalovirus infection: synthesis and antiviral activity evaluation of benzothiadiazine dioxide acyclonucleosides. *Journal of Medicinal Chemistry*, **1999**, 42, 1145-50	8.3	21
57	Lipase catalysed amidation of diethyl glutamate derivatives; peculiarities of ethyl S- and R-pyroglutamate. *Biotechnology Letters*, **1998**, 20, 261-263	3	5
56	Enzymatic alcoholysis of SO2-uracil analog diacyclonucleosides. Long-distance effect of the substituents on the regioselectivity. *Journal of Molecular Catalysis B: Enzymatic*, **1998**, 4, 295-302		2
55	Synthesis of nonsymmetrically 3,4-disubstituted 1,2,5-thiadiazole dioxides. *Journal of Heterocyclic Chemistry*, **1998**, 35, 297-300	1.9	4
54	Towards lipophilic derivatives of S-adenosyl-L-methionine. *Journal of Heterocyclic Chemistry*, **1998**, 35, 727-730	1.9	1
53	Resolution of 1-(4-amino-3-chloro-5-cyanophenyl)-2-bromo-1-ethanol by lipase mediated enantioselective alcoholysis, hydrolysis and acylation. *Tetrahedron: Asymmetry*, **1998**, 9, 2229-2232		10
52	Phosphodiesterase inhibitory properties of losartan. Design and synthesis of new lead compounds. *Bioorganic and Medicinal Chemistry Letters*, **1998**, 8, 505-10	2.9	53

51	Synthesis and Antiviral Activity of Modified 1,2,6-Thiadiazine Dioxide Acyclonucleosides. *Nucleosides & Nucleotides*, **1997**, 16, 265-276		7
50	Regioselective lipase-catalyzed synthesis of l-glutamic monoamide derivatives. Effect of the N-blocking group. *Tetrahedron*, **1997**, 53, 11745-11752	2.4	14
49	Selective carriers of norepinephrine and ammonium ions: ionophoric properties and molecular modelling studies of diester crown compounds containing a 1,3-bis(1H-pyrazol-1-yl)propane unit. *Bioorganic and Medicinal Chemistry*, **1997**, 5, 363-71	3.4	8
48	Molecular modeling of (E)-1-alkyl-4(3)-[2-(1H-azolyl)vinyl]-pyridinium salts and evaluation of their behavior towards choline acetyltransferase. *Bioorganic and Medicinal Chemistry*, **1997**, 5, 949-54	3.4	2
47	Comparative Molecular Field Analysis (CoMFA) on [6] + [6] Fused Pyrazines with Nematocide Properties. *QSAR and Combinatorial Science*, **1997**, 16, 372-376		3
46	Benzothiadiazine dioxide acyclonucleosides as lead compounds for the development of new agents against human cytomegalovirus and varicella-zoster virus infections. *Bioorganic and Medicinal Chemistry Letters*, **1997**, 7, 1031-1032	2.9	13
45	Arylimino-1,2,4-thiadiazolidinones: a new family of potassium channel openers. *Bioorganic and Medicinal Chemistry*, **1997**, 5, 1275-83	3.4	18
44	Regioselective lipase catalyzed synthesis of diester crowns. New asymmetric macrocycles containing a 1,3-bis(1H-pyrazol-1-yl)propane unit. *Tetrahedron*, **1997**, 53, 11481-11488	2.4	2
43	Applications of a statistical model to the analysis of the kinetic parameters in isothermal and non-isothermal crystallization of polymer blends based on PVDF. *Polymer*, **1997**, 38, 2741-2746	3.9	12
42	Base promoted transformation on thiadiazolopyridinium chlorides. *Journal of Heterocyclic Chemistry*, **1997**, 34, 337-340	1.9	3
41	Conformation and ortho steric effects in a series of 2-(pyrazol-1-yl)quinolines. *Journal of Heterocyclic Chemistry*, **1996**, 33, 323-326	1.9	5
40	New Synthetic Route to of 1,2,4-Thiadiazolines and 1,3-Thiazolines via Thiadiazolopyridinium Salts. *Heterocycles*, **1996**, 43, 2657	0.8	7
39	Dioxides of bicyclic thiadiazines: a new family of smooth muscle relaxants. *Bioorganic and Medicinal Chemistry*, **1995**, 3, 179-85	3.4	13
38	New 1,2,6-thiadiazine dioxide acyclonucleosides: synthesis and antiviral evaluation. *Bioorganic and Medicinal Chemistry*, **1995**, 3, 1527-35	3.4	13
37	The structure of the compounds resulting from the reaction of arylhydrazines with dehydroacetic acid: an NMR and crystallographic study. *Tetrahedron*, **1995**, 51, 4891-4906	2.4	15
36	Semiempirical (AM1, PM3 and SAM1) calculations of the protonation enthalpies of proton sponges related to 1,8-diaminonaphthalene. Estimation of the aqueous basicity of new designed superbases. *Journal of the Chemical Society Perkin Transactions II*, **1995**, 923-927		16
35	The Regio- and Stereocontrolled Ring Opening of Heteroarylglycidates with Nitrogen Nucleophiles. *Tetrahedron Letters*, **1995**, 36, 5417-5420	2	6
34	Regioselective Mucor miehei lipase catalyzed synthesis of podands containing a 1,3-bis(1H-Pyrazol-1-yl)propane unit. *Tetrahedron*, **1995**, 51, 2417-2426	2.4	9

33	Regioselective lipase-mediated acylation-deacylation in thiadiazine diacyclonucleosides.. *Tetrahedron*, **1994**, 50, 13865-13870	2.4	13
32	Tautomerism of benzo- and cyclopenta-[1,2,6]thiadiazine S,S-dioxides. *Journal of the Chemical Society Perkin Transactions II*, **1994**, 1561-1564		11
31	Thiadiazolopyridinium Salts: Intermediates for Heterocyclic Synthesis. *Heterocycles*, **1994**, 38, 1737	0.8	5
30	Synthesis and biological evaluation of 4-quinolone ribosides. *Journal of the Chemical Society Perkin Transactions 1*, **1993**, 845		14
29	The problem of the existence of C(Ar)H ? N intramolecular hydrogen bonds in a family of 9-azaphenyl-9H-carbazoles. *Journal of the Chemical Society Perkin Transactions II*, **1993**, 1547-1555		25
28	Application of ultrasonic nebulization for the determination of rare earth elements in phosphates and related sedimentary rocks using inductively coupled plasma atomic emission spectrometry with comments on dissolution procedures. *Journal of Analytical Atomic Spectrometry*, **1993**, 8, 833	3.7	11
27	SO2 extrusion in 1,2,6-thiadiazine 1,1-dioxides: a novel synthesis of pyrazoles. *Canadian Journal of Chemistry*, **1993**, 71, 410-412	0.9	10
26	The molecular structure of 3(5)-methyl-4,5(3)-trimethylenepyrazole hydrochloride and its13C and15N NMR spectroscopy. *Journal of Crystallographic and Spectroscopic Research*, **1993**, 23, 961-965		1
25	Tautomerism and acidity in 4-quinolone-3-carboxylic acid derivatives. *Tetrahedron*, **1992**, 48, 6135-6150	2.4	51
24	(E)-1-alkyl-[2-(1H-azol-2-yl)vinyl]pyridinium salts: theoretical analysis, synthesis and evaluation of their interaction with choline acetyltransferase.. *Bioorganic and Medicinal Chemistry Letters*, **1992**, 2, 1493-1496	2.9	5
23	Lipase-Mediated Acylation of Acyclonucleosides. Application to Novel Fluoroquinolone Derivatives. *Synthetic Communications*, **1991**, 21, 1477-1480	1.7	12
22	Synthesis of [CH(CN)NH] pseudopeptides. A new peptide bond surrogate. *Tetrahedron Letters*, **1991**, 32, 7579-7582	2	16
21	Synthesis and NMR spectroscopy (1H 13C) of 1-(2?-benzothiazolyl)-3(5),4-polymethylenepyrazoles and related compounds. *Journal of Heterocyclic Chemistry*, **1991**, 28, 647-651	1.9	9
20	Glycosides of Pyrido [2,3-c]-1,2,6-thiadiazine 2,2-Dioxides. *Nucleosides & Nucleotides*, **1990**, 9, 69-79		2
19	A 1H and 13c Nmr study of the structure and tautomerism of 4-pyrazolylpyrazolinones. *Journal of Heterocyclic Chemistry*, **1990**, 27, 865-870	1.9	22
18	Structure of 1,2,6-thiadiazine 1,1-dioxides. *Journal of Physical Organic Chemistry*, **1990**, 3, 470-476	2.1	11
17	Synthesis of a Valuable Precursor for the Preparation of Novel Quinolone Glycosides. *Synlett*, **1990**, 1990, 753-754	2.2	2
16	Rotational isomerism in 6-D-glucopyranosides of methyl-1,2,6-thiadiazin-3(2H)-one 1,1-dioxides. *Journal of the Chemical Society Perkin Transactions II*, **1990**, 783-786		7

15	Reaction of 4-hydrazinoquinolines with β-diketones. Synthesis and spectroscopy (1h, 13c nmr, ms) of some pyrazolylquinolines. *Journal of Heterocyclic Chemistry*, **1989**, 26, 733-738	1.9	17
14	On the Tautomerism of 2-Phenacyl-4-pyrimidinones and Related Compounds. *Chemische Berichte*, **1989**, 122, 919-924		16
13	Synthesis and cytostatic screening of an SO2 analogue of doridosine. *Archiv Der Pharmazie*, **1988**, 321, 99-101	4.3	5
12	Synthesis and spectroscopic properties of N-azolylpropanamides. *Journal of Heterocyclic Chemistry*, **1988**, 25, 225-229	1.9	14
11	Synthesis of 2S-Dioxo Isosteres of Purine and Pyrimidine Nucleosides IV. Selective Glycosylation of 4-Amino-5H-Imidazo [4, 5-c]-1, 2, 6-Thiadiazine 2, 2-Dioxide. *Nucleosides, Nucleotides and Nucleic Acids*, **1987**, 6, 631-642	1.4	9
10	N-Glucosyl-5-amino-4-carbamoyl- and 4-Ethoxycarbonylimidazoles as Potential Precursors of 4-Oxoimdazo[4,5-c]-1,2,6-thiadiazine 2,2-Dioxides. *Heterocycles*, **1986**, 24, 3451	0.8	3
9	Synthesis and intramolecular cyclization of bisthiadiazinylmethane derivatives. *Tetrahedron*, **1985**, 41, 3105-3116	2.4	8
8	Glycogen Synthase Kinase 3: A Target for Novel Mood Disorder Treatments125-154		1
7	3-Amino Pyrazoles as Potent and Selective Glycogen Kinase Synthase 3 (GSK-3) Inhibitors281-305		4
6	The Crystal Structures of Glycogen Synthase Kinase 361-82		
5	GSK-3, a Key Player in Alzheimer's Disease105-124		
4	Protein Kinase Assays for Drug Discovery189-201		
3	Marine Compounds as a New Source for Glycogen Synthase Kinase 3 Inhibitors307-331		1
2	TDZD's: Selective and ATP Noncompetitive Glycogen Synthase Kinase 3 Inhibitors257-280		2
1	Identification of NPC1 as a novel SARS-CoV-2 intracellular target		1